Aurobindo Pharma Ltd (AUROPHARMA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Aurobindo Pharma Ltd (AUROPHARMA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3314
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:62
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Aurobindo Pharma Ltd (Aurobindo Pharma) is a pharmaceutical company which develops, manufactures and exports formulations and active pharmaceutical ingredients (API’s). Its products portfolio includes active pharma ingredients, formulations, antibiotics, anti-retrovirals, anti- allergics, gastroenterologicals, anti-Diabetics, HIVs, peptides, nutraceutical and aurozymes. It also offers contract research and manufacturing services across all the clinical stages of drug lifecycle. Aurobindo Pharma conducts research and development in the areas of product identification, literature evaluation, API process development, formulation development, pilot BA or BE, exhibiting batches for dossier submission, stability studies for global requirements, and dossier submission. The company has presence in China, South Africa, Australia, Germany, Japan, the US, the UK, and others. Aurobindo pharma is headquartered in Hyderabad, Telangana, India.

Aurobindo Pharma Ltd (AUROPHARMA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Aurobindo Pharma to Acquire Generics Business of Apotex 13
Novartis May Sell US Generic Pill Business 14
Aurobindo Pharma May Acquire Dermatology Generics Business from Novartis 16
Aurobindo Pharma May Acquire Russian Business of Shreya Life Sciences 17
Intas Pharma and Aurobindo Pharma May Acquire Europen Divisions from Teva Pharma 18
Mallinckrodt May Sell Generic Drug Unit to Aurobindo Pharma 19
Aurobindo Pharma Acquires Four Biosimilar Products from TL Biopharma 20
Arrow Generiques to Acquire Select Commercial Products in France from Teva Pharma 21
Cipla and Aurobindo Acquires Certain Generic Products Rights in the US from Teva Pharma 22
Aurobindo Pharma Completes Acquisition Of Generics Operations Of Actavis In Western Europe For US$40.8 Million 23
Partnerships 25
Aurobindo Pharma Forms Joint Venture with Tergene Biotech 25
Celon Labs Forms Joint Venture with Aurobindo Pharma 26
Licensing Agreements 27
Aurobindo Pharma, Cipla, Desano Pharma, Emcure Pharma, Hetero Labs and Laurus Labs Enter into Licensing Agreement with Medicines Patent Pool 27
Aurobindo Pharma Extends its Licensing Agreement with Medicines Patent Pool 29
Aurobindo Pharma Enters into Licensing Agreement with Medicines Patent Pool 30
Aurobindo Pharma Enters into Licensing Agreement with Medicines Patent Pool for Lopinavir/Ritonavir 31
Cipla, Emcure Pharma, Hetero Drugs, Natco Pharma and Aurobindo Pharma Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb 32
Equity Offering 34
Aurobindo Pharma Plans to Raise USD300 Million in Private Placement of Shares 34
Aurobindo Pharma Receives Board Approval for Private Placement of Shares for up to USD350 Million 35
Asset Transactions 36
Aurobindo Pharma Sells Manufacturing Facility In Tamilnadu 36
Acquisition 37
Aurobindo Pharma to Acquire Additional 20% Stake in Tergene Biotech 37
Agile Pharma Acquires Generis Farmaceutica from Magnum Capital Partners for USD142.8 Million 38
Eris Pharma Acquires Aurobindo Pharma Australia from Aurobindo Pharma 39
Aurobindo Pharma Acquires Natrol for USD132.5 Million 40
Aurobindo Pharma Acquires Hyacinths Pharma for up to USD3 Million 41
Aurobindo Pharma Acquires Remaining 25% Stake in Silicon Life Sciences from ABS Mercantiles 42
Aurobindo Pharma Ltd – Key Competitors 43
Aurobindo Pharma Ltd – Key Employees 44
Aurobindo Pharma Ltd – Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Joint Venture 48
Recent Developments 49
Financial Announcements 49
May 28, 2018: Aurobindo Pharma Q4 FY17-18 and FY17-18 Financial Results 49
Nov 09, 2017: Aurobindo Pharma: Q2 FY17-18 Financial Results 51
Aug 09, 2017: Aurobindo Pharma: Consolidated Financial & Business Highlights – Q1FY18 53
Feb 09, 2017: Aurobindo Pharma Announces Q3 results & Limited Review Report for the Quarter ended December 31, 2016 54
Corporate Communications 55
Feb 09, 2017: Aurobindo Pharma Announces Change in Board of Directors 55
Legal and Regulatory 56
Mar 05, 2018: Aurobindo Pharma Issued Clarification on US FDA Observations 56
Mar 05, 2018: Aurobindo Announces Inspection of Unit 4 by US FDA 57
Mar 04, 2018: US inspectors cite serious quality issues at Aurobindo Pharma’s Unit 4 58
Apr 19, 2017: Aurobindo Pharma Provides Update on US FDA Inspection at Bachupally Manufacturing Facility 59
Product News 60
May 13, 2018: Aurobindo Pharma’s arm recalls 2 antibiotic injections from US 60
03/30/2017: Aurobindo Pharma receives USFDA Approval for Generic Epzicom tablets 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aurobindo Pharma Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Aurobindo Pharma to Acquire Generics Business of Apotex 13
Novartis May Sell US Generic Pill Business 14
Aurobindo Pharma May Acquire Dermatology Generics Business from Novartis 16
Aurobindo Pharma May Acquire Russian Business of Shreya Life Sciences 17
Intas Pharma and Aurobindo Pharma May Acquire Europen Divisions from Teva Pharma 18
Mallinckrodt May Sell Generic Drug Unit to Aurobindo Pharma 19
Aurobindo Pharma Acquires Four Biosimilar Products from TL Biopharma 20
Arrow Generiques to Acquire Select Commercial Products in France from Teva Pharma 21
Cipla and Aurobindo Acquires Certain Generic Products Rights in the US from Teva Pharma 22
Aurobindo Pharma Completes Acquisition Of Generics Operations Of Actavis In Western Europe For US$40.8 Million 23
Aurobindo Pharma Forms Joint Venture with Tergene Biotech 25
Celon Labs Forms Joint Venture with Aurobindo Pharma 26
Aurobindo Pharma, Cipla, Desano Pharma, Emcure Pharma, Hetero Labs and Laurus Labs Enter into Licensing Agreement with Medicines Patent Pool 27
Aurobindo Pharma Extends its Licensing Agreement with Medicines Patent Pool 29
Aurobindo Pharma Enters into Licensing Agreement with Medicines Patent Pool 30
Aurobindo Pharma Enters into Licensing Agreement with Medicines Patent Pool for Lopinavir/Ritonavir 31
Cipla, Emcure Pharma, Hetero Drugs, Natco Pharma and Aurobindo Pharma Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb 32
Aurobindo Pharma Plans to Raise USD300 Million in Private Placement of Shares 34
Aurobindo Pharma Receives Board Approval for Private Placement of Shares for up to USD350 Million 35
Aurobindo Pharma Sells Manufacturing Facility In Tamilnadu 36
Aurobindo Pharma to Acquire Additional 20% Stake in Tergene Biotech 37
Agile Pharma Acquires Generis Farmaceutica from Magnum Capital Partners for USD142.8 Million 38
Eris Pharma Acquires Aurobindo Pharma Australia from Aurobindo Pharma 39
Aurobindo Pharma Acquires Natrol for USD132.5 Million 40
Aurobindo Pharma Acquires Hyacinths Pharma for up to USD3 Million 41
Aurobindo Pharma Acquires Remaining 25% Stake in Silicon Life Sciences from ABS Mercantiles 42
Aurobindo Pharma Ltd, Key Competitors 43
Aurobindo Pharma Ltd, Key Employees 44
Aurobindo Pharma Ltd, Other Locations 45
Aurobindo Pharma Ltd, Subsidiaries 45
Aurobindo Pharma Ltd, Joint Venture 48

List of Figures
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Aurobindo Pharma Ltd (AUROPHARMA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Scholastic Corporation:企業の戦略・SWOT・財務情報
    Scholastic Corporation - Strategy, SWOT and Corporate Finance Report Summary Scholastic Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • LifeTech Scientific Corporation (1302):医療機器:M&Aディール及び事業提携情報
    Summary LifeTech Scientific Corporation (LifeTech Scientific) is a manufacturer, suppler and marketer of interventional medical devices for cardiovascular diseases. The product portfolio of the company includes occluders, stent graft system, delivery system, vena cava fitter, vascular plug, sizzing …
  • Bank of America Corporation:企業のM&A・事業提携・投資動向
    Bank of America Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Bank of America Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Haier Electronics Group Co Ltd:企業の戦略・SWOT・財務情報
    Haier Electronics Group Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Haier Electronics Group Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Comstock Resources Inc (CRK):企業の財務・戦略的SWOT分析
    Summary Comstock Resources Inc (Comstock) is an oil and gas company. It acquires, develops, explores and produces oil and natural gas properties. The company provides oil and gas operations such as Eagle ford Shale, Haynesville Shale and Bakken Shale in North Dakota and Montana; and North Louisiana, …
  • Bengal Energy Ltd Oil & Gas Exploration and Production Operations and Cost Analysis – 2017
    Bengal Energy Ltd Oil & Gas Exploration and Production Operations and Cost Analysis - 2017 Summary Bengal Energy Ltd (Bengal Energy), formerly Avery Resources Inc is an oil and gas exploration and production company that acquires, explores, and produces prospective light oil-weighted onshore assets …
  • Ontario Teachers’ Pension Plan:戦略・SWOT・企業財務分析
    Ontario Teachers' Pension Plan - Strategy, SWOT and Corporate Finance Report Summary Ontario Teachers' Pension Plan - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Catholic Health Initiatives:企業のM&A・事業提携・投資動向
    Catholic Health Initiatives - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Catholic Health Initiatives Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • IPCA Laboratories Ltd (IPCALAB):製薬・医療:M&Aディール及び事業提携情報
    Summary IPCA Laboratories Ltd (IPCA) is a pharmaceutical company which manufactures and markets active pharmaceutical ingredients, generics and formulations for various therapeutic areas. The company’s active pharmaceutical ingredients include anti-hypertensive, anti-malarial, diuretic and anthelmin …
  • KemPharm Inc (KMPH):企業の財務・戦略的SWOT分析
    Summary KemPharm Inc (KemPharm) is a clinical-stage specialty pharmaceutical company that offers discovery and development of proprietary new molecular entity prodrugs. The company’s product pipeline includes KP415, methylphenidate drug for ADHD; KP201/IR, KP511/ER, KP606/IR and KP746 drugs for the …
  • Seafarms Group Ltd (SFG):企業の財務・戦略的SWOT分析
    Seafarms Group Ltd (SFG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Ted Baker PLC (TED):企業の財務・戦略的SWOT分析
    Ted Baker PLC (TED) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • New Age (African Global Energy) Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary New Age (African Global Energy) Ltd (New Age) is an oil and gas company that explores and develops oil and gas fields, and oil wells. The company provides activities such as include exploration, production, appraisal and development of oil and gas assets in seven sub Saharan African countrie …
  • Coresa Sa
    Coresa Sa - Strategy, SWOT and Corporate Finance Report Summary Coresa Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Tupras (Turkish Petroleum Refineries Co):企業の戦略・SWOT・財務分析
    Tupras (Turkish Petroleum Refineries Co) - Strategy, SWOT and Corporate Finance Report Summary Tupras (Turkish Petroleum Refineries Co) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Biocodex-製薬・医療分野:企業M&A・提携分析
    Summary Biocodex (Biocodex) is a drug manufacturing company that develops and commercializes drugs. The company offers products for gastro enteric diseases, pain management, neurological and psychiatric conditions, rheumatic pains, and ENT conditions. Its products include Saccharomyces boulardii, an …
  • Young & Co.’s Brewery, P.L.C. (YNGA):企業の財務・戦略的SWOT分析
    Young & Co.'s Brewery, P.L.C. (YNGA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Cleveland BioLabs, Inc.:企業のM&A・事業提携・投資動向
    Cleveland BioLabs, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Cleveland BioLabs, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • Baxter International Inc (BAX):企業の財務・戦略的SWOT分析
    Baxter International Inc (BAX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Rexahn Pharmaceuticals Inc (RNN):企業の財務・戦略的SWOT分析
    Summary Rexahn Pharmaceuticals Inc (Rexahn Pharmaceuticals), formerly Corporate Road Show.com Inc is a biopharmaceutical company that develops and commercializes therapeutics for the treatment of cancer. The company develops anti-cancer drug candidates including Archexin that is intended for the tre …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆